DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Jois B, Asopa R, Basu S.
Somatostatin receptor imaging in non-(131) I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177) Lu-DOTATATE: Low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Clin Nucl Med 2014;
39: 505-10
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.